March 25, 2022
RFA-MD-22-008 - Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
National Cancer Institute (NCI)
The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in RFA-MD-22-008, “Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)".
The following sections of RFA-MD-22-008 have been modified (changes shown in bold italics) to reflect the participation of NCI in this Funding Opportunity Announcement (FOA).
Part 1. Overview Information
Components of Participating Organizations
Currently reads:
National Institute on Minority Health and Health Disparities (NIMHD)
Modified to read:
National Institute on Minority Health and Health Disparities (NIMHD)
National Cancer Institute (NCI)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
Currently reads:
93.307
Modified to read:
93.307, 93.393
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Text has been added to reflect NCI's research interests (after):
NIMHD strongly encourages the use of standardized measures for constructs related to health disparities research. Studies conducted with human participants should use individual and structural social determinants of health (SDOH) measures that are available in the Social Determinants of Health Collection of the PhenX Toolkit (www.phenxtoolkit.org).
National Cancer Institute (NCI):
The NCI supports research that aims to reduce cancer risk, incidence, and death and enhance quality of life for cancer survivors. Ensuring that cancer patients, caregivers, and the public have access to accurate information and combatting cancer-related misinformation are critical priorities for NCI.
Of particular interest to NCI are applications that seek to:
- Assess the impact of cancer-related misinformation on healthcare delivery across the cancer continuum (i.e., prevention, screening, treatment, survivorship, end-of-life), patient-provider relationships, decision-making, and all cancer-related outcomes;
- Identify influential sources of cancer misinformation, understand their motives, and ascertain the tactics they use across different platforms, languages, and contexts;
- Develop and test mitigation strategies to combat cancer misinformation through multilevel solutions (e.g., fostering health and science literacy, building a robust system for fact-checking and debunking myths, training healthcare providers and/or community members to respond effectively to misinformation);
- Facilitate the dissemination of critical, evidence-based cancer information across the care continuum in clinical systems and community settings to ensure equitable information access and fill any “cancer information voids”;
- Identify communities that are particularly susceptible to cancer-related misinformation, elucidate factors that make them vulnerable (e.g., those with limited health literacy or limited English proficiency, members of marginalized or medically underserved groups, immigrant and diaspora communities), and develop targeted mitigation interventions;
- Use tools and mixed methods approaches to monitor the information environment in real-time, identify the dynamics of cancer misinformation spread, and analyze non-textual data online (e.g., videos and images).
Additionally, applicants are encouraged to build non-traditional partnerships with community organizations, media outlets, and technology platforms to understand and address cancer misinformation.
Section II. Award Information
Funds Available and Anticipated Number of Awards
Currently reads:
NIMHD intends to commit $2 million in FY 2022 to fund approximately 3 awards.
Modified to read:
NIMHD intends to commit $2 million in FY 2022 to fund approximately 3 awards. NCI intends to commit $1M in FY2023 to fund approximately 2-3 awards.
Section VII. Agency Contacts
Currently reads:
Nancy L. Jones, Ph.D., M.A.
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8945
Email: nancy.jones@nih.gov
Michelle Doose, Ph.D., MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-402-4620
Email: michelle.doose@nih.gov
Arielle Gillman, Ph.D., MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-435-0060
Email: arielle.gillman@nih.gov
Modified to read:
Nancy L. Jones, Ph.D., M.A.
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8945
Email: nancy.jones@nih.gov
Michelle Doose, Ph.D., MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-402-4620
Email: michelle.doose@nih.gov
Arielle Gillman, Ph.D., MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-435-0060
Email: arielle.gillman@nih.gov
Wen-Ying Sylvia Chou, PhD, MPH
National Cancer Institute (NCI)
Telephone: 240-276-6954
Email: chouws@nih.gov
Financial/Grants Management Contact
Currently reads:
Priscilla Grant, J.D.
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8412
Email: grantp@mail.nih.gov
Modified to read:
Priscilla Grant, J.D.
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8412
Email: grantp@mail.nih.gov
Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov
All other aspects of this FOA remain the same.
Wen-Ying Sylvia Chou, PhD, MPH
National Cancer Institute (NCI)
Phone: 240-276-6954
Email: chouws@nih.gov
and Human Services (HHS)
